A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.
“First, Congress could explicitly allow the participation of contract pharmacies in the 340B program given their importance in securing revenue for 340B [covered entities] and ensuring patient access to low-cost drugs,” Aaron Kesselheim, Ryan Knox, and Ameet Sarpatwari say in an opinion article published online on April 15.
A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
